Cannabis extracts and methods of preparing and using same

• US 9,730,911 B2
• Filed: 10/21/2015
• Issued: 08/15/2017
• Est. Priority Date: 10/21/2014
• Status: Active Grant

• Current Assignee: Nascent Pharma LLC
• Original Assignee: United Cannabis Corporation
• Inventors: Verzura, Tony, Blackmon, Earnie
• Primary Examiner(s): SHIAO, REI TSANG
• Application Number:
  US14/919,245
• Publication Number:
  US 20160106705A1
• Time in Patent Office: 664 Days
• Field of Search: 514454, 514729, 514568
• CPC Class Codes: A61K 31/05 Phenols cannabinoids A61K31/658
• CPC Class Codes: A61K 31/192 having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid cannabinoids A61K31/658
• CPC Class Codes: A61K 31/352 condensed with carbocyclic rings, e.g. methantheline cannabinoids A61K31/658
• CPC Class Codes: A61K 31/353 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• CPC Class Codes: A61K 36/185 Magnoliopsida (dicotyledons)
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/22 Anxiolytics
• CPC Class Codes: A61P 25/36 Opioid-abuse
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention relates to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance (BDS) for incorporation in to a medicament. It also relates to a BDS, for use in pharmaceutical formulations. In particular it relates to BDS comprising cannabinoids obtained by extraction from cannabis.

Claims

1. A liquid cannabinoid formulation, wherein at least 95% of the total cannabinoids is tetrahydrocannabinolic acid (THCa).

2. The formulation of claim 1, further comprising at least one terpene/flavonoid.

3. The formulation of claim 2, wherein the terpene/flavonoid is d-limonene linalool, 1,8-cineole (eucalyptol), α

-pinene, terpineol-4-ol, p-cymene, borneol, Δ

-3-carene, β

-sitosterol, β

-myrcene, β

-caryophyllene, cannflavin A, apigenin, quercetin or pulegone.

4. The formulation of claim 2, wherein the formulation comprises no more than 4% terpene.

9. The formulation of claim 1 or 5, wherein the formulation comprises no more than 4% terpene, wherein said terpene comprises myrcene, caryophyllene, and limonene.

33. The formulation of claim 1, 5, 10, 16, 20, or 25, formulated for oral, sublingual, buccal, or topical administration.

34. The formulation of claim 33, wherein the sublingual formulation further comprises a sweetener.

35. The formulation of claim 34, wherein the sweetener is a stevia extract.

36. The formulation of claim 34, further comprising lemon oil, orange oil or both.

5. A liquid cannabinoid formulation, wherein at least 95% of the total cannabinoids is tetrahydrocannabinol (THC).

6. The formulation-of claim 5, further comprising at least one terpene/flavonoid.

7. The formulation of claim 5, wherein the formulation comprises no more than 4% terpene.

8. The formulation of claim 6, wherein the terpene/flavonoid is d-limonene linalool, 1,8-cineole (eucalyptol), α

-pinene, terpineol-4-ol, p-cymene, borneol, Δ

-3-carene, β

-sitosterol, β

-myrcene, β

-caryophyllene, cannflavin A, apigenin, quercetin or pulegone.

10. A liquid cannabinoid formulation, wherein at least 95% of the total cannabinoids is cannabidiol (CBD).

11. The formulation of claim 10, wherein the formulation further comprises less than 1% THC.

12. The formulation-of claim 10, further comprising at least one terpene/flavonoid.

13. The formulation of claim 10, wherein the formulation comprises no more than 4% terpene.

14. The formulation of claim 12, wherein the terpene/flavonoid is d-limonene linalool, 1,8-cineole (eucalyptol), α

-pinene, terpineol-4-ol, p-cymene, borneol, Δ

-3-carene, β

-sitosterol, β

-myrcene, β

-caryophyllene, cannflavin A, apigenin, quercetin or pulegone.

15. The formulation of claim 10, wherein the formulation comprises no more than 4% terpene, wherein said terpene comprises myrcene, caryophyllene, and limonene.

16. A liquid cannabinoid formulation, wherein at least 95% of the total cannabinoids is THCa and cannabidiolic acid (CBDa).

17. The formulation-of claim 16, further comprising at least one terpene/flavonoid.

18. The formulation of claim 16, wherein the formulation comprises no more than 4% terpene.

19. The formulation of claim 17, wherein the terpene/flavonoid is d-limonene linalool, 1,8-cineole (eucalyptol), α

-pinene, terpineol-4-ol, p-cymene, borneol, Δ

-3-carene, β

-sitosterol, β

-myrcene, β

-caryophyllene, cannflavin A, apigenin, quercetin or pulegone.

24. The formulation of claim 16 or 20, wherein the formulation comprises no more than 4% terpene, wherein said terpene comprises myrcene, limonene, pinene, and caryophyllene.

20. A liquid cannabinoid formulation, wherein at least 95% of the total cannabinoids are THC and CBD.

21. The formulation-of claim 20, further comprising at least one terpene/flavonoid.

22. The formulation of claim 20, wherein the formulation comprises no more than 4% terpene.

23. The formulation of claim 21, wherein the terpene/flavonoid is d-limonene linalool, 1,8-cineole (eucalyptol), α

-pinene, terpineol-4-ol, p-cymene, borneol, Δ

-3-carene, β

-sitosterol, β

-myrcene, β

-caryophyllene, cannflavin A, apigenin, quercetin or pulegone.

25. A liquid cannabinoid formulation, wherein at least 95% of the total cannabinoids are CBD, cannabinol (CBN) and THC.

26. The formulation of claim 25, wherein the formulation comprises less than 9% THC.

27. The formulation-of claim 25, further comprising at least one terpene/flavonoid.

28. The formulation of claim 25, wherein the formulation comprises no more than 4% terpene.

29. The formulation of claim 27, wherein the terpene/flavonoid is d-limonene linalool, 1,8-cineole (eucalyptol), α

-pinene, terpineol-4-ol, p-cymene, borneol, Δ

-3-carene, β

-sitosterol, β

-myrcene, β

-caryophyllene, cannflavin A, apigenin, quercetin or pulegone.

30. The formulation of claim 25, wherein the formulation comprises no more than 4% terpene, wherein said terpene comprises myrcene, pinene and caryophyllene.

31. The formulation of any one of the proceeding claims, wherein the formulation is infused in a medium chain triglyceride (MCT).

32. The formulation of claim 31, wherein the MCT is NEOBEE 895.